The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
JacksonN.A.BarruecoJ.Soufi-MahjoubiR.Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combination in elderly versus nonelderly patients with metastatic colorectal cancer. Cancer.2009; 115: 2617–2629.
2.
FuchsC.MarshallJ.MitchellE.Randomized, controlled trial of irinotecan plus infusional bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol.2007; 25(25): 4779–4786.
3.
PattY.LeeF.LiebmannJ.Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer. Phase II trial results. Am J Clin Oncol.2007; 30(4): 350–367.
4.
KoopmanM.AntoniniN.DoumaJ.Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. Ann Oncol.2006; 17(10): 1523–1528.
5.
KoopmanM.AntoniniN.DoumaJ.Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet.2007; 370(9582): 135–142.
6.
ReaR.NortierJ.Ten Bokkel HuininkW.A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol.2005; 16(7): 1123–1132.
7.
SkofE.RebersekM.HlebanjaZ.OcvirkJ.Capecitabine plus irinotecan (XELIRI Regimen) compared to 5-FU/LV plus irinotecan (FOLFIRI Regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer.2009; 9: 120–128.
8.
MoehlerM.SprinzlM.AbdelfattahM.Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol.2009; 15(4): 449–456.
9.
LearyA.AssersohnL.CunninghamD.A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemother Pharmacol.2009; 64(3): 455–462.
10.
KohneC.H.De GreveJ.HartmannIrinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC Study 40015. Ann Oncol.2008; 19(5): 920–926.
11.
CartwrightT.LopezT.VukeljaS.Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer.2005; 5(1): 50–56.
12.
GennatasC.MichalakiV.GennatasS.Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer. Anticancer Res.2008; 28(38): 1923–1926.
13.
ZhaoR.ZhuJ.JiX.A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer. Jpn J Clin Oncol.2010; 40(1): 10–16.
14.
ParkS.BangS.ChoE.First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. Oncology.2004; 66(5): 353–357.
15.
BajettaE.BartolomeoM.MarianiL.Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer.2004; 100(2): 279–287.
16.
MeropolN.GoldP.DiasioR.Thymidine Phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol.2006; 24(25): 4069–4077.
17.
BornerM.BernhardJ.DietrichD.A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol.2005; 16(2): 282–288.
18.
Garcia-AlfonsoP.Munoz-MartinA.Mendez-UrenaM.Capecitabine in combination with irinotecan (XELIRI) administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI Group. Br J Cancer.2009; 101(7): 1039–1043.
19.
ChoiC.ChanR.TungS.Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma – a dual-centre Phase II study: the MAC-6. Clin Oncol.2008; 20(2): 168–175.
20.
MoehlerM.SprinzlM.AbdelfattahM.Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol.2009; 15(4): 449–456.
21.
RosatiG.CordioS.BordonaroR.Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Ann Oncol.2010; 21(4): 781–786.
22.
HofheinzR.Gnad-VogtU.WeinA.Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study. Anti-Cancer Drugs.2005; 16(1): 39–45.
23.
KimT.KangW.ChangH.Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group Trial. Acta Oncol.2005; 44(3): 230–235.
24.
BaekJ.KimJ.JeonS.Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Br J Cancer.2006; 94(10): 1407–1411.
25.
SunQ.HangM.XuW.Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer. Jpn J Clin Oncol.2009; 39(12): 791–796.
26.
LuoH.WangZ.WangF.Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer. Am J Clin Oncol.2011; 43(6): 555–560.
27.
OhS.SurH.SungH.A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer. Br J Cancer.2007; 96(10): 1514–1519.
28.
WillekeF.HorisbergerK.Kraus-TiefenbacherU.A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (Caplri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer.2007; 96(6): 912–917.
29.
HanJ.LeeD.LeeS.Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naïve patients with advanced non-small cell lung carcinoma. Cancer.2005; 104(12): 2759–2765.
KrisM.G.HeskethP.J.SomerfieldM.R.American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
TerreyJ.P.AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
36.
CarmichaelJ.KeizerH.J.CupissolD.MilliezJ.ScheidelP.SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anti-Cancer Drugs.1998; 9(5): 381–385.
37.
de WitR.de BoerA.C.vd LindenG.H.StoterG.SparreboomA.VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85(8): 1099–1101.
38.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
39.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
40.
GelingO.EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
41.
PicusJ.MartinM.G. Gastrointestinal complications of chemotherapy. In: PerryM.C., ed. The Chemotherapy Sourcebook.4th ed.Philadelphia, PA: Lippincott Williams and Wilkins; 2008: 197–208.
42.
MarounJ.A.AnthonyL.B.BiaisN.Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. Curr Oncol.2007; 14(1): 13–20.
43.
BensonA.B.AjaniJ.A.CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol.2004; 22(14): 2918–2926.
44.
SmithT.J.KhatcheressianJ.LymanG.H.2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
CartwrightT.McCollumD.BoehmK.Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer. Am J Clin Oncol.2010; 33(3): 307–313.
FloydJ.MirzaI.SachsPerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33: 50–67.
49.
MedlinJ.PerryI. Hepatotoxicity of chemotherapeutic agents. In: PerryM.C., ed. The Chemotherapy Sourcebook.4th ed.Philadelphia, PA: Lippincott Williams and Wilkins; 2008: 209–222. ■
